Podcasts about rfs

This Farm Talk segment features Tracey Olson, COO at Guardian Energy Management and North Dakota Corn Growers Association Industry Representative. Olson discusses the recent EPA announcement of proposed RFS volume obligations for 2026 and 2027. See omnystudio.com/listener for privacy information.

Steven Johnson, retired Iowa State Extension farm management specialist; Ken Ericksen, Polaris Analytics and Consulting, trends in ag trade and barge transport

Von Christine Mayrhofer. Von 13. bis 15. Mai sind Österreichs Studierende zur Wahl aufgerufen. Was versprechen und fordern die elf antretenden Listen und Fraktionen? Und wieso ist die Wahlbeteiligung bei ÖH-Wahlen traditionell so niedrig?

A bi-partisan letter from U.S. Senators was sent to EPA urging the agency to raise RFS volumes. Paul Winters, director, public affairs and federal communications for Clean Fuels Alliance America, joins us to discuss the details. This week's Farmer Forum features Tim Burrack of Iowa and Sherman Newlin of Illinois.See omnystudio.com/listener for privacy information.

Tomm Pfitzenmaier, Summit Commodity Brokerage, says grains end mostly lower with risk off selling and positioning ahead of President Trump's Liberation Day announcement on tariffs. Soybean oil was the one exception as its been up the last few days on word of a possible deal to increase the blending mandate for biomass based diesel in the RFS. Cattle were also higher with live cattle making some new contract highs, while hogs fell on tariff fears. See omnystudio.com/listener for privacy information.

Welcome to The Football Historian Podcast, hosted by Peter Kenny Jones. Grégory Vignal is back for his second interview on The Football Historian Podcast, as he reflects on last year's Liverpool Legends game and his career. Before facing Chelsea at Anfield, the French defender answered some quickfire questions in our first Magical History Tour. Whilst he was in the garage Grégory also took part in three more videos which you can watch on YouTube: Playing With Myself | Gregory Vignal | Fifa 2003 | PS2 https://youtu.be/mmrWb7BioYo My Football Shirt History | Gregory Vignal Football History Wars | Gregory Vignal Thanks so much for the feedback and don't forget to keep sending questions for future guests to thefootballhistorianpodcast@gmail.com Hope this instalment of your soon to be favourite football podcast continues to impress! CHAPTERING 00:35 - Gregory Vignal 00:55 - Liverpool Legends & Sven-Göran Eriksson 03:28 - RFS & Coaching Today 05:10 - Meeting Jürgen Klopp 07:59 - Liverpool This Season 11:13 - Rangers This Season 12:43 - Quickfire Questions 29:51 - The Debate 31:01 - Red Card Want more from The Football Historian Podcast? Listen to or watch the exclusive EXTRA section of this interview via our Patreon. It's just £1 per month for the first 100 patrons! You also get a monthly special, entered into prize draws and access to our entire back catalogue! https://www.patreon.com/TheFootballHistorianPodcast Keep up to date with all our latest clips on our socials: Instagram: https://instagram.com/thefootballhistorianpod/ TikTok: https://tiktok.com/@thefootballhistorianpod X: https://twitter.com/TheFHPod Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode of Agriculture Today, we'll learn about some reports that the USDA will once again be distributing, takeaways from the most recent USDA supply and demand report, continued debate over the RFS, and some comments from the U.S. EPA administrator on the review of crop protection tools.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Rīgā pārspējot Amsterdamas "Ajax", RFS kļuva par pirmo Latvijas futbola klubu, kas izcīnījis uzvaru Eirokausu pamatturnīrā. Astoņās spēlēs iegūti pieci punkti, ierindojoties 32. vietā. Lai noskaidrotu, kurš futbolists visvairāk pacēla savu vērtību, ko starts UEFA Eiropas līgā nesa Latvijai un kas tika izdarīts nepareizi, sagaidot "Ajax" ultras, Ulvis Brože studijā aicināja Sportacentrs.com futbola cilvēku Agri Suveizdu un "Go3" futbola komentētāju Arkādiju Birjuku. Sportacentrs.com podkāsts Ārpus kadra – katru trešdienas vakaru kanālā TV4, portālā Sportacentrs.com un visās populārākajās audio straumēšanas platformās. Ārpus kadra 2025. gadā uz priekšu dzen oficiālais KTM un MERIDA velosipēdu pārstāvis Latvijā AstraVelo, bet podkāstam veldzi nodrošina Vytautas minerālūdens

On Tuesday's AOA, we kick off the show with an update on 45Z, RFS and more with Kurk Kovarik from Clean Fuels Alliance America. Then we continue our coverage of the AgMarket.net “Farming for Profit, Not Price” conference and have a conversation with Dan Basse from AgResource Company. Then, we sit down with Matt Bennett from AgMarket.net in Segment Three and close the show with a cattle market outlook from Ross Baldwin of AgMarket.net.  

"Lufthansa" kā stratēģiskais investors palielinās "airBaltic" vērtību; potenciālajiem investoriem interesē uzņēmuma nākotnes peļņa. Ārpolitikas debates: nepieciešams atbalstīt Ukrainu un stiprināt savu aizsardzību. Latvijas Banka aicina hipotekāro kredītu ņēmējus vairāk izmantot pārkreditēšanās iespējas, lai nepārmaksātu par šiem aizdevumiem. Latvijas čempioni futbolā RFS aizvadīs pēdējo maču UEFA Eiropas līgas pamatturnīrā jeb līgas fāzē. Prezentē pirmo elektrovilcienu, kurš aprīkots ar velosipēdu pārvadāšanai paredzētajiem stiprinājumiem. Līdz ar pilna apmēra iebrukumu Krievija tās okupētajās teritorijās Ukrainā aktivizējusi ukraiņu bērnu apmācību militārām iemaņām, tādejādi gatavojot mobilizācijas rezerves Krievijas armijai.

De griepgolf heeft ook de Pantelic Podcast bereikt, maar Bart en Jan zorgen online toch gewoon voor een nieuwe Pantelic Podcast. En dat is maar goed ook, want het is de week van de waarheid voor Ajax. Met Galatasaray, maar vooral De Klassieker aankomende zondag staat er nogal wat op het programma. Ze bespreken de wedstrijden voor, maar ook zeker de andere manier waarop het de week van de waarheid is. Namelijk die voor Alex Kroes. Het is nog still op de transfermarkt. En Kroes is na vijf maanden terug bij af, want Carlos Forbs lijkt de nieuwe (oude) linksbuiten te gaan worden. Hij moet nu echt aan de bak met de naderende transfer deadline!(00:00) Intro(01:20) Nog even RFS(10:10) Druk op Kroes neemt toe(25:55) Uitgaand gebeurt er wel wat(31:28) Interesse in Cedric Hatenboer(34:08) Speculaties rond Brobbey(39:46) Galatasaray zonder Ziyech in de Arena(43:18) De Klassieker(52:32) Het Pantelic Plakboek(56:32) Jong Ajax stelt teleurZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Our first Europa League match-day of the year! The week kicked off in dramatic fashion around Istanbul - Kyiv stunning Galatasaray on Tuesday with a comeback draw for their first point of the campaign, then Besiktas taking it to Athletic Club on Wednesday in Ole Gunnar Solskjær's first game in charge. Thursday featured a slate of big clubs going head-to-head, where Sociedad, Roma, Fenerbahce failed to show up, pushing them dangerously close to missing out on qualification. Elsewhere, Tottenham and Hoffenheim remain maddeningly inconsistent, and RFS pulls off their first ever Europa League win against the mighty Ajax. We also turn to January 30's games - the final match-day of the inaugural League Phase - and discuss all the important fixtures and table scenarios. Cheers Dino Toppmöller!

15min tinklalaidėje apie Lietuvos ir pasaulio futbolą „Skrieja kamuolys“ – žaidimų konsolės, geriausiųjų rinkimai, Vilniaus „Riterių“ investuotojai, „draugiškos“ Matijaus Remeikio rungtynės su Rusijos klubu, brangiausia futbolininkė istorijoje, „Bayern“ paslydimas Roterdame, „El Cashico“, Čempionų lygos formatas, nauja geriausia komanda pasaulyje, A.Chusanovo kliurkos ir kitoks „Manchester City“ žaidimas, vargo vakarienė „Tottenham“ bei „Manchester United“ stovyklose, Mariaus kelionė į Rygą, kur RFS paguldė „Ajax“, ispanų, vokiečių ir italų lygos. Prie mikrofonų – 15min sporto žurnalistai Aurimas Tamulionis ir Marius Bagdonas bei „Go3“ komentatoriai Rytis Vyšniauskas ir Karolis Dudėnas. 00:00 Konsolės ir Mariaus prisiminimas iš vaikystės 07:44 Geriausi Lietuvos metų futbolininkai 12:08 Kas tie Vilniaus „Riterių“ investuotojai? 18:24 Lietuvos klubų kontroliniai mūšiai 32:13 Gineitis turės dar vieną konkurentą? 33:31 Kiti lietuviai svetur ir Remeikio mačas su rusais 37:07 Salės futbolas ir brangiausia futbolininkė istorijoje 40:10 „Bayern“ sumuštas Roterdame, „Man City“ – Paryžiuje 51:09 Kaip jums naujasis Čempionų lygos formatas? 1:06:10 Istorinė savaitė Lietuvos teisėjams 1:08:37 Geriausia komanda pasaulyje ir „Liverpool“ 1:20:59 Chusavono kliurkos, Pepas ir kitoks „Man City“ 1:32:43 „Tottenham“ ir „Man United“ vargas 1:39:51 RFS paguldė „Ajax“ – Mariaus įspūdžiai iš Rygos 1:45:42 K.Mbappe hat-trickas ir G.Neville‘o šmėkla 1:53:50 Į gynybą atsitraukęs „Bayer“ ir pramušęs H.Kane‘as 2:02:44 „Napoli“ aukštaūgiai ir cirkai Milane

Rechtstreeks uit het vliegtuig vanuit Letland probeert Arco met Freek de kater van de 1-0 nederlaag van Ajax bij RFS weg te spoelen in een nieuwe aflevering van de Pak Schaal Podcast. Hoe was het in Riga? Ook de concrete interesse in Brian Brobbey van West Ham United pakken we mee.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Un poco de competiciones mainstream: qué va a pasar en la última jornada de la Champions y quién va a ser el portero del Barça en los próximos partidos. Y el underground habitual: cosas de copas portuguesas, del histórico triunfo del RFS letón, de la gran aparición del momento en la segunda española... También: Rueda de Prensa y Comunicado por el Borrado del Podcast Efímero.

Een wanvertoning van Ajax in Letland. Er werd met 1-0 van RFS verloren. Bart Obbink en Jan Verdonk spreken het na in de Wedstrijdeditie.Wedstrijdwoord niet gewonnen en toch 'Eenmalige Ajacieden' willen lezen?Bestel hem dan op: https://boekengilde.nl/boekenshop/eenmalige-ajacieden/?srsltid=AfmBOoprtZVdSRy5vaNGwUSgp1Oh3shzb7iNxw_uQ0c8rgY3lpGaH9mUZie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

Feyenoord kwam een dag na de zege op Bayern München met duidelijkheid over de positie van de trainer. Brian Priske mag blijven bij de club uit Rotterdam. En dat na dagen van speculaties over zijn positie. In de Europa League wonnen AZ en FC Twente hun wedstrijd. Ajax verloor in Riga met 1-0 van RFS na een hele slechte wedstrijd. In de AD Voetbalpodcast bespreekt Etienne Verhoeff met Sjoerd Mossou deze zaken en Lex Lammers kijkt naar de KKD. ,,Die quotes van Dennis te Kloese zeggen niet zo veel en is gezwets in de ruimte", vertelt Mossou over het aanblijven van Priske. ,,Na grote twijfels en een crisisberaad waarbij ze dachten aan een ontslag, mag hij toch blijven. Als je de optelsom met de voors en tegens naast elkaar, vind ik het wel een logische conclusie dat Priske mag blijven. Bovendien: wat is het alternatief? Wie is er beschikbaar als vervanger?"Ook bespreken ze Europese avond in de Europa League. ,,Het was bijna een perfecte week voor de Nederlandse club in Europa en de coëfficiëntenlijst. Alleen Ajax liet het afweten in Riga. Dat was wel een afgang in de Europese geschiedenis van de club." Beluister de hele AD Voetbalpodcast nu via AD.nl, de AD App of jouw favoriete podcastplatform. Vergeet je niet te abonneren op de podcast. Dan krijg je elke dag de nieuwe show automatisch in je playlist.Support the show: https://krant.nlSee omnystudio.com/listener for privacy information.

Režisora Ginta Zilbaloža animācijas filma "Straume" kļuvusi par pirmo Latvijas filmu, kas nominēta ASV Kinoakadēmijas balvai jeb "Oskaram". Esam tikai ceļa sākumā un būs vajadzīgs laiks, lai izstrādātu stratēģiju attiecībā uz noregulējumu Ukrainā - Tā atzinis prezidents Edgars Rinkēvičs. Teju par piekto daļu pieaudzis sankciju pārkāpumu skaits. Visvairāk liedz izvest automašīnas. Turpmāk pārtikas iepakošanai vairs nevarēs izmantot uzpūstu un presētu putuplasta iepakojumu Latvijas čempioni RFS savās mājās uzņems slaveno Amsterdamas Ajax.

The roller coaster of news concerning the continuing resolution means getting the perspectives of a variety of folks concerned with U.S. agriculture. We discuss the ag economy and rural banking with Alan Hoskins, president of American Farm Mortgage & Financial Services. Robert White, senior vice president of industry relations and market development at the Renewable Fuels Association, talks about E15 and the RFS. Paul Neiffer, a.k.a. The Farm CPA, also chimes in about the status of the CR and farm aid.See omnystudio.com/listener for privacy information.

מכבי תל אביב ניצחה אמש (חמישי) 1:2 את RFS הלטבית בליגה האירופית והכניסה את עצמה לתמונת העלייה לפלייאוף של המפעל כשהיא עם שש נקודות. הצהובים שרדו דרמה מוכרת, כזו שהתרחשה רק לפני שבוע בדיוק, כאשר בדקה ה-100 הפועל חדרה השוותה אחרי פנדל שרועי משפתי הצליח להדוף. הפעם, משפתי שבעצמו גרם לפנדל, הצליח גם לקלוט את הכדור באופן סופי ולהבטיח ניצחון לצהובים, שמצד אחד יכולים לשמוח ולחגוג, אבל מצד שני חייבים להבין איך האירועים האלה קורים להם שוב (פנדל שלישי העונה אחרי הדקה ה-90). וגם: הבישולים של פטאצ׳י, השערים הקשים של נחמיאס וסטואיץ׳, הדקות האחרונות וההתנהלות של תורג׳מן, דוידה ויחזקאל, הראיון של לאזטיץ׳ ובחירת השחקנים שלו בתוך המערך שבו הוא מאמין. רז אמיר ואורן קדוש מסכמים ניצחון באירופה תמונת קאבר: רויטרסSee omnystudio.com/listener for privacy information.

Nacionālā elektronisko plašsaziņas līdzekļu padome varēs ierobežot un bloķēt pirātiska satura tīmekļvietnes. To paredz Saeimā pieņemtie Autortiesību likuma grozījumi. Saeima galīgajā lasījumā pieņēma lēmumu par pensiju automātisku pārrēķināšanu no 2026. gada 1. janvāra strādājošiem pensionāriem. Latvijas Pensionāru Federācijā uzskata, ka tas ir solis pretī sudraba ekonomikai. Valsts prezidents nepieņem, ka pašvaldību nākamie mēri un viņu vietnieki varētu palikt bez pielaides valsts noslēpumam. RFS futbolisti atsāk dalību Eiropas līgā un aizvadīs spēli Belgradā.

On this weeks podcast, I speak with NSW Rural Fire Service Area Commander Southwestern Chief Superintendent Kelwyn White. Kelwyn commenced her service with the NSW Rural Fire Service in 2002 and, since then has worked across NSW in District, State, and Area-based roles. Kelwyn has been both a salaried officer and a volunteer during her service. Kelwyn's commitment, especially in Community Risk & Community Engagement, is held in the highest regard by her peers and the community. Kelwyn continues to be a proud advocate for engaged communities, playing a significant leadership and mentoring role in this field to NSW RFS membership and the community. Kelwyn is passionate about sharing her knowledge to help others achieve their desired outcomes, as a keen advocate for training, she gives her time to develop others. When Kelwyn commenced with the RFS, she started in administration and has worked her way through the ranks to be one of the 7 Area Commanders and, currently the only female in this role.  During this time, Kelwyn has been fortunate to see the evolution in the way women are seen and operate within the RFS and is proud to have been a part of that.  Yet knowing that, there is more to come and is proud to be in a position to support, encourage and mentor women to develop into leadership roles, or simply be the best version of themselves they can be within emergency service or their own lives. As the Area Commander for the Southwestern Area, Kelwyn is responsible for the coordinated fire-fighting arrangements across the Area, including mitigation of bushfire risks to the community through strategic organisational programs to reduce risk to the community from bushfire and other emergencies and ensuring communities are engaged, prepared and warned appropriately before and during an emergency. Presenter: Adam Blum Guest: Kelwyn White Editor: Kyle Watkins Investigative Consultant: Adam Holloway

Piedāvājam portāla Sportacentrs.com futbola apskatnieka Edmunda Novicka plašu (2h un 40min.) sarunu ar futbola kluba RFS prezidentu Artjomu Milovu.

In the wake of the elections in the US, RINS Reporter Matthew Cope and US Products Associate Editor Jason Metko play a game of "hit the brakes or hit the gas" to discuss some of the potential effects on the biofuels industry - particularly important to the Renewable Fuel Standard (RFS) and road fuels - under a second Donald Trump administration.  Listen to find out if it's "hit the brakes" or "hit the gas" as we address issues including: Should we expect Small Refinery Exemptions (SREs) to return under the new Trump administration? Trump's pick to lead the Environmental Protection Agency (EPA), Lee Zeldin, previously backed a bill to eliminate the RFS. Would he do that now? Trump has expressed the desire to get rid of electric vehicle (EV) subsidies. However, with Elon Musk operating an EV company, will he push Trump for more incentives? Biden took a less favourable approach towards E15. Will it be different with Trump's return?

On this episode of Agriculture Today, we will learn about how the renewable fuel standard will be tackled under a second Trump administration, President-elect Trump's past positions on Waters of the US, animal activist ballot measures from the last election, US Custom Harvesters priorities when it comes to the H-2A guest worker visa program, and an outlook for beef demand from the 2024 Kansas Livestock Association convention.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Eiropas Parlamentā 7. novembrī turpinās jauno Eiropas Komisijas locekļu izjautāšana pirms izšķirošā balsojuma novembra beigās. Šodien iztaujā Valdi Dombrovski. Plāno ieviest stingrākas prasības tālmācības skolām. Saeima izdod ZZS deputātu Jakovinu kriminālvajāšanai viltotas ārsta izziņas lietā. RFS futbolistiem 7. novembrī spēle pret Beļģijas "Anderlecht", bažas rada pretinieku kvēlie fani. Cik tālu Kremlis ir gatavs iet, lai ietekmētu ASV prezidenta vēlēšanas?

Một cuộc tàn sát chết người ở miền trung Sudan do lực lượng bán quân sự RFS thực hiện đã khiến ít nhất 124 người thiệt mạng và hàng chục người dân địa phương bị thương và phải di tản. SBS News đã nói chuyện với một phụ nữ Úc gốc Sudan ở Sydney, người có các thành viên trong gia đình đã thiệt mạng, bị thương và phải di tản trong các cuộc tấn công, trong khi người anh trai 27 tuổi Ibrahim của cô vẫn mất tích.

This week, the leader of Sudan's Rapid Support Forces (RSF) militia accused Egypt of supporting its opponent, the Sudanese military. Lieutenant General Mohamed Hamdan Dagalo, also known as Hemetti, said in a video message that the development marks an escalation of the conflict. Egypt has denied the accusations. Hussein Shingrai is the foreign affairs secretary of the People's Democratic Party of Sudan. He says Sudan as a sovereign country has the right to buy weapons from wherever it wants. Shingrai tells VOA's James Butty, Hemetti may be trying to blame his apparent defeat on other countries

Šią savaitę 15min tinklalaidėje apie Lietuvos ir pasaulio futbolą „Skrieja kamuolys“ – sodininkų profesija, Vilniaus „Žalgirio“ stadiono akcija, netikėtas kavos protmūšis, Gargždų „Bangos“ pagirios ir pagyros, ruletės spalvos, Armandinijo10 įvarčiai, Čempionų lygos minusai, Eriko ten Hago pasakos, turkų baubas latviai, siaubinga trauma, geriausias žaidėjas Ispanijoje ir karštas ginčas dėl kaukėtojo Vincento Kompany. Komanda – 15min sporto žurnalistai Aurimas Tamulionis ir Marius Bagdonas bei „Go3“ komentatoriai Rytis Vyšniauskas ir Karolis Dudėnas. 00:00 Sodininkų profesija ir ar metamės „ant stadiono“ Vilniaus „Žalgiriui“? 05:33 P.Golubicko šokiai Šiauliuose ir netikėtas protmūšis 13:18 „Bangos“ pagirios ir pagyros, ką daryti Telšiams bei ruletės spalvos 29:26 Armandinijo10, Japonija ir „Katastrofos“ procentai 37:03 Čempionų lygos minusai, karštas ginčas dėl V.Kompany ir RFS baubas 1:08:15 ETH pasakos, „Liverpool“ tvarkaraštis ir švaistūnas A.Traore 1:33:48 Šaukliai Madride, baisiausia trauma ir geriausias žaidėjas Ispanijoje 1:43:03 Vartininkai – sienos, šunelių akcija ir G.Gineičio perdavimas

36 games games in the Europa and Conference Leagues have come and gone, and we have a LOT to talk about! In the Europa, we had a thriller in Porto, smaller clubs getting huge upset results ( RFS (!), Elfsborg, Twente, Anderlecht), bigger clubs struggling (Galatasaray, Fenerbahce, Roma, Sociedad), and Tottenham youngsters stormed the gates in Hungary. Meanwhile in the Conference, Chelsea continued their scintillating form, Fiorentina did Fiorentina stuff, Betis fell in Poland, and Cercle Brugge ran riot on St. Gallen. Plus, we discuss the proposed changes to the Welsh Cup. All that and more on this week's show! Cheers, Oscar Hiljemark (P.S. - Stop being so handsome)!

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate of Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation, and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-the-power-of-tax-free-income

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate of Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation, and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-the-power-of-tax-free-income

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia andLondon, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-guaranteed-income-streams

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard.Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-qualified-funds-how-is-too-much

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA, and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia and London, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard.Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-qualified-funds-how-is-too-much

Michelle has over 20 years of experience in Financial Services and her main goal is to always focus on her client's long-term financial planning strategy to optimize retirement income.She prides herself on analyzing a financial situation, finding any potential issues, and creating adequate solutions to ensure her clients' prosperous future. With her extensive insurance and planning experience, Michelle adds great knowledge to the already specialized team at RFS.She has worked in various capacities in the financial industry from being part of top producer teams to teaching new financial advisors through agency leadership. Michelle's passion is to help educate consumers by taking complex financial strategies and explaining them in an easy way to understand the concept. Michelle is originally from Pittsburgh, PA and a graduate from Penn State University in Business.She now resides in Boynton Beach, FL with her husband Rob, their two daughters Olivia andLondon, and their three pets. When Michelle isn't working with RFS's clients or spending time with her family, she is likely exercising or on her Peloton, competing her way to the top of the leaderboard. Michelle has always loved sports as she grew up playing Basketball, Volleyball, and Softball. While living in Pittsburgh, she became part of Steeler Nation and that devotion has carried with her to South Florida.Michelle joined Rosenzweig Financial Services in October 2021 as Vice President, specializing in the professional marketplace.Learn more: https://www.rfsny.com/Registered representative of, and securities and investment advisory services offered through Hornor, Townsend & Kent, LLC (HTK), Registered Investment Adviser, Member FINRA/SIPC, 1 North Federal Hwy, Suite 201, Boca Raton, FL 33432. 561-314-3100, http://www.htk.com. HTK is a wholly-owned subsidiary of The Penn Mutual Life Insurance Company. Rosenzweig Financial Services is unaffiliated with HTK. HTK does not offer tax or legal advice. Always consult a qualified adviser regarding your individual circumstances.Retirement Income Authority is not affiliated with HTKInfluential Entrepreneurs with Mike Saundershttps://businessinnovatorsradio.com/influential-entrepreneurs-with-mike-saunders/Source: https://businessinnovatorsradio.com/interview-w-michelle-boyce-ricp-vp-w-rosenzweig-financial-services-discussing-guaranteed-income-streams

How does a routine backburn turn into a large-scale emergency covering 100 hectares? Join us to uncover the harrowing story of a Saturday on the Northern Beaches of Sydney where the Rural Fire Service (RFS) faced an unexpected and intense challenge. We'll take you through the critical moments of this dramatic day, celebrating the exceptional courage and relentless efforts of the RFS personnel. You'll gain insights into how effective information dissemination plays a crucial role during such emergencies, thanks to the timely updates from our trusted local source, the Manly Observer.In this episode, we also shine a light on the importance of community awareness and responsible use of emergency services. Discover the benefits of staying informed with resources like the RFS app and the indispensable role of reliable news outlets. We extend our deepest appreciation to the RFS and the Manly Observer for their invaluable contributions. Don't miss this compelling conversation about the heroes who protect our community and the critical importance of staying informed during crises.

Raidījums “(Bez)maksas sports” - informatīvi analītisku un izglītojošu stāstu un diskusiju raidījums par lielajiem jautājumiem Latvijas un pasaules sportā. 2. sezonas 3. epizodes tēma: Futbols ir sporta karalis. Jā, lai gan daudzi to atzīt nevēlas - arī Latvijā. Futbolā apgrozās citiem sporta veidiem teju neaptveramas naudas summas, kam klāt šosezon nāks RFS kluba nopelnītie miljoni UEFA Eiropas līgā. Kāda ir finansiālā situācija Virslīgā? Cik liela ir plaisa starp Latvijas vadošajiem un pārējiem klubiem? Līgā ienākuši vairāki ārzemju investori - kāpēc un ar kādu mērķi? Kāda iezīmējas virslīgas attīstības vīzija un, vai virzīt uzdevumu futbola klubs kā peļņas avots, ir utopija? Studijā: Tukums 2000/Telms prezidents Verners Akimovs un Virslīgas valdes priekšsēdētājs Maksims Krivuņecs. Raidījumu vada Jānis Celmiņš. Viedokļos dalās: Leevon PPK prezidents Jurijs Žigajevs, RFS ģenerāldirektors Māris Verpakovskis un FK Liepāja direktors Dāvids Jansons. Mediju atbalsta fonda ieguldījums no Latvijas valsts budžeta līdzekļiem. Par raidījuma saturu atbild TV4. #SIF_MAF2024

A Gallifrey One guest announcement tops the RFS headlines as Jenna Coleman aka Clara Oswald is set to arrive in Los Angeles this upcoming February! Plus Russell T Davies is in the latest SFX to explain how TV works to you nerds, so what better time for the Three Who Rule to add their uninformed insights to the pile? An Emperor Davros dolly is on the way from B&M, Ncuti Gatwa's theatrical spectacular The Importance of Being Earnest heads for cinema screens and more, before a Classic Series Commentary on the penultimate episode of both “Planet of the Spiders” and the Jon Pertwee era!  Links: Support Radio Free Skaro on Patreon Jenna Coleman announced as guest of Gallifrey One RTD says Season 3 renewal won't come until after Season 2 airs BFI redux screening of The Happiness Patrol on September 29 B&M 2024 Remembrance of the Daleks – Emperor Davros B&M 2024 The History of the Daleks #18 Ncuti Gatwa's The Importance of Being Earnest getting UK cinema release Doctor Who finalists for five BAFTA Cymru Awards (aka The Welshies) Breakdown of the first scene of The Power of the Daleks Commentary: Planet of the Spiders Episode 5

Part 1 is devoted to the final round of UEFA club competition qualifying & the upcoming league phase in the three tournaments. We look at the Larne, TNS, RFS & Slovan Bratislava underdog success stories, amazing social media posts involving the Smurfs and Mr. Bean, the changed format of the three club competitions and the computerised draw, plus the best European groundhops you could make to take in the league phase action. In Part 2, we divide our time between domestic club football and the international game. A broken goal is met with the suggestion of blowtorch repair in the Icelandic top tier, Papua New Guinea's Admiralty Islands FC relocate to the mainland for six months and the international break looms large with three standout fixtures: San Marino vs. Liechtenstein, Comoros vs. Madagascar and Guyana vs. Suriname. If you don't want to wait until 18 September for our next episode, then you can join us for a bonus podcast on 11 September at patreon.com/SweeperPod. You will also be able to read our blog about the 2024 Greenlandic Football Championship, enter the draw to win a B67 shirt, become part of our growing Discord community and get exclusive content from our trip to watch San Marino take on Liechtenstein in Serravalle. RUNNING ORDER: 00:00 – Intro 03:04 – UEFA qualifiers: Upsets & underdogs 09:00 – UEFA qualifiers: Media & memes 14:13 – UEFA qualifiers: Unfamiliar formats 18:56 – UEFA qualifiers: Groundhopping guidance 24:29 – Collapsing goals in Iceland & Romania 30:56 – Papua New Guinea's relocating islanders 36:56 – San Marino & the international break 44:12 – Patreon perks & B67 shirt giveaway Editor: Ralph Foster

RFS improves trucks, communications and safety.

In this episode of the Just Schools Podcast, Jon Eckert interviews Dr. Bobby Ott, superintendent of Temple ISD and 2022 Texas Superintendent of the Year. They discuss integrating mental health services, special education needs, and innovative teaching practices. Dr. Ott highlights the importance of developing a mental health services model in schools, addressing funding and expertise limitations. He also stresses retaining specialized teachers and improving preparatory models for special education and English language learner programs Additionally, the conversation explores AI and technology's potential to transform education, advocating for proactive leadership to enhance personalized learning and prevent misuse. The Just Schools Podcast is brought to you by the Baylor Center for School Leadership. Each week, we'll talk to catalytic educators who are doing amazing work. Be encouraged. Books Mentioned: Brave New Words by Sal Khan 1000 CEOs by Andrew Davidson Connect with us: Baylor MA in School Leadership Jon Eckert LinkedIn Twitter: @eckertjon Center for School Leadership at Baylor University: @baylorcsl   Transcription: Jon Eckert: So today we're here with Bobby Ott, the superintendent of Temple ISD. He's the 2022 Superintendent of the Year for the state of Texas and a good friend of Baylor and our program. He always has a lot of wisdom to share. And so today we're going to talk a little bit about some of the challenges that he sees facing students in Temple and Texas in general and maybe just across the country because many of these issues transcend different places. Certainly they're context-specific, but broader issues. And Bobby has a pretty good handle on what's going on in Texas and has a wide network. So we're grateful to have Bobby here today. So Bobby, thanks for all you do. Just tell us a little bit about what you've been dealing with the last month or so. We'll roll in with that first and then jump into those bigger questions. But can you just update us on your world over the last month? Bobby Ott: Well, the last couple weeks for sure has been a little bit of a whirlwind, and I guess that's both figuratively and literally. But as you may know, we had three tornadoes in Temple touch down within about a 30-mile radius. And so the community really looked apocalyptic when you drove through it. Some places you couldn't drive because of debris. And of course we still had a week and a half of school left, so that caused some challenges at the 11th hour. But having a great team and a great community, number one, we were truly blessed to not have a single fatality in a natural disaster of that magnitude. So that was first and foremost. And as I shared earlier with others, to me that is certainly a divine hand being involved in that. I have never heard of a situation that had that type of catastrophe and not have a fatality. But I did send a video out, kind of a peek behind the curtain of the things we had to plan for, and we were able to make it through the last week. We were able to meet the bureaucratic requirements, which in my mind are secondary compared to the human elements of graduation, kids being in a safe environment, staff feeling safe, displaced staff having a place to be and so forth. And so now we were able to make it through that. The stress level has gone way down. And at this point, I'm just dealing with insurance adjusters and trying to figure out how to close out a budget year with deductible payments that I didn't expect to have. But anyway, we're working through it. The community is slowly getting back to normal and just blessed to have the partnerships that we do in the community and just the great hands and hearts that work together and pull together to get everybody through. Jon Eckert: No, and the video you shared was powerful because as we prepare superintendents and principals at Baylor, we try to help them anticipate every eventuality. You've taught in that. We have a number of sitting superintendents that teach in that. But until you've been through something like that, it's really hard to know what that looks like. And so I thought the video was helpful just as you went over the board and what's there. As we talk today, I want to focus in on student-centered issues that you see. Obviously, your point about the divine providence that comes in and keeps people safe in a natural disaster, that's real. There are day in, day out challenges that our kids face and resilience that they have to display and community support that they need to be successful. And so you're talking to us as we launch Cohort 8 of our EDD that's preparing superintendents. And so they're going to do three years of research on a problem of practice that they care deeply about that matters in the context they're in. And so what I'm interested in is hearing from superintendents about two or three of the biggest issues you see that need attention in the research, in data collection, but really in the practical day in and day out of how do we make life better for students? How do we do that in a way that's life-giving, that leads to flourishing, and makes sure that we're moving forward in useful ways when you're not dealing with insurance adjusters and all the budget pieces, which are real. And those have to be dealt with, otherwise you can't serve kids well. But if you were to say, "Hey, these are the two or three things that I see." That as people think about what they might research and dedicate three years of their lives to research-wise, what would come to mind as you think about that right now? Bobby Ott: And this certainly isn't in rank order, but one would be a true model of integrating. And when I say model, something that's repeatable that you could replicate in any district size, but a true model for integrating mental health services in a school district. I got to be honest with you, every year when we're sitting down as a group of superintendents, whether it's countywide or regionwide, there's always this discussion about how to truly integrate mental health services in a school system. And several districts have tried different things. They've tried some co-op services. They've tried to hire on regular counselors and get them trained in certain things and then they peel off. But there's two limitations that we find ourselves in a lot of times, and one is expertise. Rightly or wrongly, school counselors a lot of times do not have that level of expertise that we're talking about. They maybe have a general background in how to work those issues, in particular social, but the mental health pieces we find some real limitations and expertise. And then of course funding because truth be told, people that have that level of expertise make more money outside of public schools and the private sector is far more attractive and pays a lot better. So what we find ourselves doing is trying to find retirees from the private sector, people that only want to work part-time, people that really like the schedule of public schools. But people that are experts in that field could stand to make more money than the principal of the campus for sure. And so it just becomes very, very difficult. There are some very specialized skills that are required to do those kinds of things. And counselors that come out of the traditional school education track they're really equipped only to a certain line and our students are needing beyond the line. And when they try to seek outside support, a lot of times the students that have those needs do not have the resources to secure the outside support, whether it's monetary or accessibility with parents being able to get them where they need to go and so forth. So I think one, so what does that look like in terms of research? When you told me about this, I try to think about it in two lenses. One, what would be the problem? And maybe what is a approach in terms of resource or research? And I would say researching models to embed specialized counseling services, trauma-informed care, restorative practices, cognitive therapy into credentialing for counselors in their traditional track programs. Maybe therapy-specific coursework, maybe there's a way. I think we're trying to address the problem after people are certified, but I wonder if there are models that can be done between a traditional public education track in grad school in partnership with the college of psychology or behavioral sciences or something like that. And I don't know the answer to that. That's a little bit outside of my expertise. But I think there's some different directions for students there. Cohort 8 could look at maybe a preparatory model or you could look at a service model in the school system. So that would be the first one. Jon Eckert: No, that's a powerful one. And we're working in Mississippi right now with five districts because there's high levels of opioid use and abuse. And the mental health piece is such a huge part of it because you're dealing with communities that are struggling with some of that and then that is bleeding into the kids and some of the trauma that comes with that. And trying to figure out ways to put universal interventions in place that get kids making better choices that lead to thriving communities so you're less likely to make those choices is hard. But then when they've already made the choices, you need really specific interventions by highly trained people. And one of the things we've been doing in schools over the last few years is a lot of trying to fill in the gaps for people without training. And it gets really dangerous when you start trying to identify and diagnose and you have educators who are desperate for help and feel these urgent needs, but then they don't have the training. And so sometimes they can exacerbate the problem without that expertise. So I think that's tremendously insightful and needed. So what would be the next one that you have? If you were to say, "Hey, tackle this," and you said not in order, but what would be something else you would say we should be tackling? Bobby Ott: Well, the other thing that we're seeing, and this really points to special program services in particular, English language learners and special education, but those numbers are going up across the state. And there's a couple of reasons for it. I mean, I think one is generational. We're seeing that more and more in the younger generations. You're seeing more students in kinder and first with not just disabilities, but language delay and also high needs, and I'll get into that piece in a second. But the numbers go up and the funding has gone down. And so the ratios are a big problem in that mix because there are required ratios for very, very specialized programs. And when funding is going down, even the IDEA federal grant has reduced, what funds typically special education services. But the other piece is your qualifiers have expanded too. So for example, adding dyslexia to special ed has totally increased that number in every single school district. And so when those things happen, you start to pull apart the service in the program. It really starts to dilute. And so that's where we're at on that end. The other piece is RFs or residential facilities. We are really struggling because one, there's not enough residential facilities in said communities, but two, they are very liberal about denying even if they have enough beds in long and short-term placement. It literally is one of the hardest things you can possibly do to get students to qualify for a residential facility. And so what happens is those students a lot of times in schools end up becoming what I call in and outs. They're in, and then the next episode they're out. And so they never really improve educationally or anything else because we are not equipped within the school system to appropriately deliver the services those students need. And so when they're denied those services from the outside, even through referral processes, and there's a lot of complications with that, could be resources at home, it could be insurance, could be a lot of things. It could be that sometimes parents don't like to get them qualified because they'll lose some of their financial assistance. And I've run into that quite a bit too. So that's a real problem. That is a population in total that is growing, funding is not growing commensurate with the program, and specialized services are very selective for which students can be accepted and not accepted. So what's the research angle there? I mean, that's a good question. And this sounds a little bit like maybe the first one, but maybe there are different models of partnerships that we can work with students that are denied residential. I mean, there's a zone of students that we don't know how to take care of appropriately and what do we do with those students? Are there transitory programs? Are there effective practices and how we can train people to work with higher ratios or to handle students that are episodic? We are so ill-equipped in that area. And when the students don't have anywhere else to go, the default is us. And at that point, we're really not doing them a justice. We're just not. And it's heartbreaking. It's really heartbreaking. But that's something that I think would be very encouraging if there were some type of transitory model or something that can be put together. That's on the RF side. I think the other side of it, just regular special education and English language learner piece. What I find is that those are harder and harder to hire even if you do get the stipends up. I think there is an exodus of people leaving that were serving special education students. And what I hear, or what's reported to me rather through exit interviews, documented exit interviews is a lot of times it's the paperwork piece that comes with it. And this is what I don't know. It almost appears like it's a surprise. And I don't know if in prep programs there's a lot of attention given to the detail of the paperwork piece that comes with teaching in a special program because there seems to be an element of surprise when teachers are leaving and they're explaining, "Well, I didn't realize I had to do all this for RDs, I had to do all this for IEPs, I had to do all this and computer systems," and this, that and the other. And it is heavy. I mean, certainly it does carry a different weight with regard to that piece than say the regular education teacher. So that is something that I wonder at times. I don't know if that's something that's strong on the research side. I mean, obviously higher ed doesn't have the authority to minimize the bureaucratic requirements. But the time they spend with advocates, the time they spend in meetings and they walk, a lot of times they walk. And so maybe a way that we can figure out how to help school districts put together very specific teacher retention programs for special education. What does that look like? Retaining a special education and bilingual teacher that's not like retaining a general ed teacher. What does that really look like? And what are some ideas that school districts could do with helping specialized teachers with higher ratios if it comes to that? And then how can we work with students that should be in a residential facility are denied or maybe there isn't bed space or they're in for a month and they're sent back when they should have been in longer? What can we do there? So that'd be the second one. And that's probably not as succinct as the first one, but maybe there's enough directions you can go out of that. Jon Eckert: No, that's powerful and overlaps nicely with the first one. Obviously, mental health is going to weave through all of that. And so the mental health of special education teachers is also part of it. And I think you can tell people and you can prepare people say, "Hey, this is a lot of paperwork. Here's the way you're going to have to do this. These are legal contracts you're creating. This is not going to be a light lift." I think though the reality doesn't hit you until you're actually in it. Because I think most people drawn to special ed really care deeply about kids and that's what gets them... And I think it's true for teaching in general, but I think especially special ed. And then when you're hit with and you're going to have a lot more paperwork. And so you can say it, and then you live the reality and it feels different. So if you have one other challenge that you see that could use some research, some deeper thought, do you have one more in mind or anything that builds off of these two? Otherwise, we can jump to a couple other questions. Bobby Ott: I think the other one would be the general idea of pacing. There is, and this has happened probably for the last 10 years, but there seems to be this growing amount of what needs to be taught in terms of standards and the level of intricacy, which whether it's multi-step problems, high-rigor written responses, you name it. I certainly agree with testing and rigor and depth, but I disagree with the idea that the timing that teachers have to truly get students to understand things at that level and then we're adding more and more standards. To me that starts to dilute the whole entire system of public education. It becomes kind of this mile wide, inch deep versus the inverse. And so it really... I feel like as a system that we are heading toward a system of testing and minimal completion over true learning and engagement. And this is greatly because of the influence of a lot of the special interests that we're always trying to include in standards, bureaucratic systems, standard setting. And the kids really suffer greatly. And I don't know if teachers really get a handle on that piece of it because it continues to grow. So research angle, innovative teaching practices that know how to maximize time engagement, content with a group of students that are on different parts of the continuum. I know that we have things like that in prep programs, but I just think that that's something we need more and more. And I do think that we probably ought to start really considering the use of technology in a way to minimize some of the basic steps in education. And that kind of gets to the question of what opportunities do you see for educators? And I can expand on that now or wait until you comment on the third area. Jon Eckert: No, that's great. We want to jump into opportunities. Where do you see some optimistic next steps? So certainly jump right into that and then we can expand on that a little bit. Bobby Ott: I think technology use. I know AI can be received in many different ways because I've seen it firsthand. Some people turn and walk. Some people think it's a great thing. But I would love to see AI used in a way that allows the teacher to be set up in a classroom in a more intimate way with instruction and allows them to go into depth. I'm wondering if AI in tandem with a classroom teacher could create an environment where the larger nominal content can be delivered in a way in masses and the teacher can become more of, I don't want to say tutor, but someone that goes in and can either provide the enrichment or remediation in smaller groups in a classroom. I'd love to see AI shrink the classroom. And I think there's ways that that can be done. Now, I'm an administrator, so I wouldn't dare try to come up with ways without teachers being involved, but I think we almost have to get to that level. And I can't think of anything else cost-effective. I mean, you can always add more teachers in a classroom, but at some point in time that becomes a budget buster. I just wonder if there's a way to handle this through technology. So I think there are opportunities with the development of AI. I think the main thing about it is we have to lead that. It can't be something done organically because if it is students will grab a hold of that and trust me they will lead it in their own way and sometimes in an abusive way that shortchanges learning. And if that happens, then they're going to be ill prepared, number one. And number two, we're going to be spending our time as administrators doing damage control. So I think it's something we have to get ahead of. I'll tell you, we're looking as a district to have an AI conference, not this summer, but next summer, and invite school districts. We're really trying to do some things to lead the way in that. This summer is kind of a standup summer in terms of educating our staff and making sure that our network is set appropriately so we minimize abuse as much as possible. So we're doing that, but I don't see enough models out there that are something that are make take, you can grab a hold of and implement in a district. So I think there's probably some opportunity for educators there. Jon Eckert: Well, I just listened to a podcast, I haven't read the book yet, but Brave New Words by Sal Khan. He obviously with Khan Academy has influenced the learning of millions of kids, but he's super optimistic about what AI can do and creating this personalized and shrinking the classroom. And he certainly doesn't minimize the role of teachers, but it's fascinating. So I definitely need to read that. We hear about AI all the time, and you're right, you have this broad range of responses. And the challenge is going to be that is moving so rapidly that it's really hard to keep out in front. And I agree we have to. But in a world where we have been doing mile wide, inch deep for forever, William Schmidt, I think he was at Michigan State, he coined that phrase about US curriculum 30, 40 years ago. And so we've been doing this because that's what I think we do a little bit in democracies. If you can't all agree, then just put it all in. Don't narrow, just add. And so you have your special interest groups, you have all these different people that are like, "Hey, this is important." And it is important, but it can't all be important. You have to figure out ways to master things. And maybe AI can be helpful there. And I think being thoughtful about that and digging in what that means to really engage students well because Sal Khan says it, kids that are already motivated will learn really well with AI. It's the kids who are not. It's the kids with mental health issues. It's the fact that teaching is a very human endeavor. How do we make it even more human using tools? Because AI is just the newest range of tools. So it certainly doesn't replace the human being because ultimately large language models are just scraping what's on the internet. So it's consensus, not wisdom. So you certainly can learn, but if you really want to become all of who you're created to be, that requires wisdom. And so that's where the humans are there. The problem is, to your point earlier, teachers are stretched so thin and so many demands are being placed on them it's really hard to have that one-on-one interaction. It's hard to really be seen, known, and loved in a system that's not set up for that. And so if AI can help with that, I certainly am excited to see where that goes. So love that you're thinking that way. If you maybe have one other opportunity you see ahead for Temple specifically or for educators in general, what gives you some hope right now? Where do you see hopeful direction in what we're doing here in Texas? Bobby Ott: I am seeing more and more leaders leading authentically and with feeling. And I'm probably saying that in a odd way, but I see large district leaders, superintendents, and principals striking at being as personable as your smaller school. Ones are really, you don't have a choice because you're everywhere. But I see more of that and I see more of this, and I try to do it as much as... Just this shameless, this mobilizing of people to shamelessly remind others why they do it. They love children, they love staff. And as bad as the political rhetoric has been against public ed generally, I think it's mobilized educators, in particular leaders, teachers have done this night and day, leaders to say, "Hey, that doesn't characterize the entire profession. We are human. We do love our children. This is what we do. This is why we do it." And I see more of that. I really see more of that. I hear more of that when I go to conferences, when I network with superintendents. Yeah, our conversations could largely be dominated by budget and bonds and the newest innovative program and so forth. But I hear more of things like, "You know, you could get that done in your community if your community truly knows that you love their children, if your staff feels appreciated." And I think there are a lot of reasons for this effort. I think retaining people in the profession is one. But you can only go so far with money. You can only go so far with things. But positive culture, that is number one. I've always said people don't leave a job. They leave a boss because they're going to get the same job somewhere else. So this idea of how you treat people and how you demonstrate appreciation and care, I think for me, I am seeing more and more of that. I'm seeing more and more of that in the people we hire in administrative positions. I'm seeing things like that on social media. Several years ago I'd see, "Hey, we graduated 653, congratulation to the graduates." And now I'm seeing videos of a student hugging their superintendent and lifting them up off the ground and the superintendent commenting saying, "This is what it's all about." I'm just seeing more of that, whether it's small or big. And I think there's been a void of that. And I see this idea of when I get into administration, business and logistics taking over my life, that there's a real attempt to say, "It may take over my tasks, but I'm still going to put out in front my community, my students, my teachers, my school nutrition workers, and hold them up." And so that is giving me a lot of hope right now. Jon Eckert: That's great. And so these last two questions can be as short or as long as you need them to be, but on a daily basis now, given everything that you're managing, and you just highlighted a little of this, where do you find joy in the work you're doing on a daily basis? What do you go back to to maintain the joy that you seem to have in the midst of a lot of different pressures and challenges? And then the second one is is there a book that you've read in the last year that you're like, "Hey, every leader, every educator, this is a great book. This was helpful"? It doesn't even have to be in the last year. If it's something from earlier, that's great. But I always like to know those things. So where do you find your joy? What's a great book? And then we can wrap up. Bobby Ott: I find my joy in the idea that good people are still good people and they exist in the masses. So I try to make sure to connect people as much as possible to those situations. We do Mission Mondays. My entire central office every Monday is on a campus opening doors for kids that are going to school, walking in classrooms, helping to serve breakfast, do those kinds of things. I think that those kinds of things bring me joy because I see it bring them joy. I see kids get excited when there's more than the same caring adult around them, but there's others that maybe they don't even know their names right away but they know that they're in the same system that they are. It brings me joy when I see people that are normally away from kids in their job reminded of why they got into this whole profession because we put together possibilities where they are around kids. I see teachers with smile on their faces because they see a genuine care from people that aren't doing their jobs but are asking to support them. We always support people behind the scenes in our various roles, but to do it right next to someone while they're real time and to see what they're actually doing. So those kinds of things bring me joy. Just watching great educators no matter where they're at in the system making the difference in each other's lives, in students lives. So that brings me joy. And then a book that comes to my mind. I don't read a lot of educator books. I'm sorry, but I don't. I read a lot of... I do read leadership books. But there's a book called 1000s CEOs and it's by Andrew Davidson. And it really takes top CEOs and puts them in containers like visionaries, strategists, motivators, innovators, organizers, what have you. And these CEOs talk about their strategies in which the container that they're, I guess labeled in as being most effective. And so there's a lot of really good strategies in there. There was one called, a group called Startup Titans. And when we were going to implement blended learning for the first time, I wanted to hear some of the strategies of deployment from CEOs that startup companies because it was so brand new in our district. So that for me was a really, really good book. I'll warn you, if it says 1000 anything, that means it's going to be a thick book because there's a lot of pages in it. But it could be a resource. You could look at a table of contents like I did and said, "Hey, we're going to start blended learning in Temple ISD, which container would make the most sense?" Well, innovator container would make sense, a visionary one, and maybe startup titans. So I would go and read some of the CEOs strategies in those areas and then try to formulate my thoughts around deployment and so forth. So that's a book that I read and am happy to pass on. Jon Eckert: No, that's super helpful. And I think sometimes in education, we get too caught up in naval gazing, just looking at what we can learn from education. And there's a lot of fields out there that have a lot of wisdom that we can glean. And especially in the role of a superintendent where you're a politician, you're a community organizer, you're a bureaucrat, you're a manager. There's so many different hats you wear, and a human being that finds joy in the good people that you work with and the community that you serve. That's super helpful because the CEO wears many of those hats. And so I think that's great wisdom. Well, hey, Dr. Ott, thank you so much for the time. Thanks for all you do for us at Baylor, for students and staff in Temple, and then for everybody across the state of Texas. We're grateful to have you so close and your willingness to serve educators in this way. So thank you. Bobby Ott: You bet. Thank you. And I wish all the best to Cohort 8. You're entering a great program. And the one thing I would say, I don't know if this is going to them or not, but the one thing I would tell them is a lot of times when you start things like a program, people will start to ponder this idea of journey versus destination kind of thing. Which one's more important? Is it getting the doctorate? Do I try to enjoy it along the way? It's heavy, whatever it may be. And what I would pass on to you is this, anytime you find yourself being asked that question or contemplating it, the answer is neither. It should always be the company. The company is the most important thing. It's not the journey or the destination, it's the company. And so enjoy your professors, enjoy your cohort, get to know the people around you, and that will be the most important thing. And if you do that, I will tell you the journey and the destination will take care of itself. Jon Eckert: Such great advice. And that's true for everybody, not just people starting a doctoral cohort. But appreciate how you live that out, and I'm grateful that you're on the journey with us and you're part of the company that we get to keep. So thanks again. Bobby Ott: You bet. Take care.    

Delays on EPA announcement of Renewable Fuel Standard volumes have become old hat for ag industry watchers, but adding in the looming election and a recent Supreme Court decision, the hurdles for regulators to get 2026 volumes published are mounting. But even as anxious corn and soybean growers watch, and some advocates prepare to sue, hope springs from ongoing conversations about the potential for US growers to participate in the Sustainable Aviation Fuel, or SAF, market in the future. To help us digest all the news, DTN Environmental Editor Todd Neeley joins us today with the latest updates from EPA and beyond. We'll talk about the RFS delays, the announced levels that have led to a few biodiesel plant closures, and updates out of California on E-15 that might provide some relief in an uncertain market. Then we'll take a deep dive on the current state of play for SAF, digging into the potential opportunity, the timeline, and what technologies and policies are still needed to make the market a reality. Finally, we'll dig into how the recent Supreme Court decision on Chevron deference might impact the biofuels space, and other issues Todd will be watching between now and November.

Kurt Kovarik, vice president, government affairs at Clean Fuels Alliance America, joins us to discuss their petitioning EPA to reconsider RFS volumes. The flooding in the Midwest and higher rivers have damaged some infrastructure, including railroads. Soy Transportation Coalition executive director Mike Steenhoek reports on the situation. And USB CEO Lucas Lentsch wraps up the month of June in this week's episode of the Soy Checkoff Check-in.See omnystudio.com/listener for privacy information.

What's all this hype around renewable diesel?  To help us dig into this topic, Matt Makinson comes back to join hosts Ryan Priest and Sal Sama for this episode of The High Ground powered by Premier Companies.  Matt is the Vice President of Supply and Marketing for CountryMark, and he's got a lot to share regarding what's happened in the two years since he joined us last!You'll hear about the latest CountryMark news and their renewable diesel co-processing project which involves expanding the capacity in the refinery and adding the capability to process soybean oil.  In addition to sustainability, you'll learn about the other benefits of renewable diesel, what goes into creating the product, and how it's different from biodiesel.  In addition to learning about how this project will help increase the overall output, you'll learn how this project will help hedge against RFS compliance costs if RIN prices go up.  If you're wondering what the Renewable Identification Number system is all about and how it impacts growers in the first place, you'll learn about that and more!

What's all this hype around renewable diesel?  To help us dig into this topic, Matt Makinson comes back to join hosts Ryan Priest and Sal Sama for this episode of The High Ground powered by Premier Companies.  Matt is the Vice President of Supply and Marketing for CountryMark, and he's got a lot to share regarding what's happened in the two years since he joined us last!You'll hear about the latest CountryMark news and their renewable diesel co-processing project which involves expanding the capacity in the refinery and adding the capability to process soybean oil.  In addition to sustainability, you'll learn about the other benefits of renewable diesel, what goes into creating the product, and how it's different from biodiesel.  In addition to learning about how this project will help increase the overall output, you'll learn how this project will help hedge against RFS compliance costs if RIN prices go up.  If you're wondering what the Renewable Identification Number system is all about and how it impacts growers in the first place, you'll learn about that and more!

Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.    TRANSCRIPT Dr. Diwakar Davar: Hello and welcome to the ASCO Daily News Podcast. I'm your guest host, Dr. Diwakar Davar, and I am an associate professor of medicine and the clinical director of the Melanoma Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. I am delighted to have my colleague and friend Dr. Jason Luke on the podcast today to discuss key late-breaking abstracts and advances in immunotherapy that were presented at the 2024 ASCO Annual Meeting. Dr. Luke is an associate professor of medicine, the associate director of clinical research, and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center.   You will find our full disclosures in the transcript of this episode.  Jason, it's always a pleasure to hear your insights on the key trials in these spaces and to have you back as a guest on this podcast that highlights some of the work, especially advances, that were just presented. Dr. Jason Luke: Well, thanks very much for the invitation. I always love joining the podcast. Dr. Diwakar Davar: We'll start very quickly by talking about some advances and really interesting things that happened both in the context of melanoma but also in immunotherapy in general. And we'll start with what I think was certainly one highlight for me, which was LBA2, the late-breaking abstract on the NADINA trial. It was featured in the Plenary Session, and in this abstract, Dr. Christian Blank and colleagues reported on the results of this phase 3 trial of neoadjuvant ipi-nivo. This is the flipped dose of ipi1/nivo3 versus adjuvant nivolumab in PD-1 naive, macroscopic, resectable, high-risk stage 3 melanoma.  By way of background, neoadjuvant immunotherapy for those listening is an area of increasing interest for drug developers and development for both approved and novel agents. Neoadjuvant immunotherapy has been studied with multiple approved agents, including PD-1 monotherapy, PD-1 LAG-3, PD-1 CTLA-4, T-VEC, as well as investigational agents and multiple randomized and non-randomized studies. The benchmark pathologic response rates with these agents range from 17% PCR with PD-1 monotherapy, 45% to 55% PCR with PD-1 CTLA-4 combination therapy, and slightly higher 57% PCR with PD-1 LAG-3 has recently reported by Dr. Rodabe Amaria from MD Anderson. However, as we embark on phase 3 comparisons for various neoadjuvant compared to adjuvant immunotherapy trials and combinations, we're increasingly moving towards event-free survival as the primary endpoint for neoadjuvant versus adjuvant studies. And this was most recently studied in the context of SWOG S1801, a study that was led by Dr. Sapna Patel.  So, Jason, before we start on NADINA, can you briefly summarize the SWOG S1801 trial and the event-free survival statistic reported by Dr. Patel and her colleagues? Dr. Jason Luke: Well, absolutely. And these data were reported at ESMO about two years ago and then in the New England Journal last year. The S1801 study answered a very simple question: What would happen if you took three of the doses of standard adjuvant therapy with pembrolizumab and moved them prior to surgery? And on a high level, the study is as simple as that. And many of us were somewhat skeptical of this trial design because we thought that just moving the doses earlier may not actually have a major impact.  In the study, you alluded to the event-free survival statistic, and that alludes to what was considered an event. And so, without reading all of it, there were several different aspects that were included in terms of time, based on the date of randomization until the first of a series of events, such as disease progression, toxicity from treatment, if the patient was unable to go to surgery or had surgical complications, or if they had delay in starting the adjuvant therapy due to toxicity, and obviously, recurrence of melanoma or death from any cause. In that context, merely moving the 3 doses of pembrolizumab to the neoadjuvant setting saw an improvement in this two-year event free survival to 72% for the neoadjuvant therapy compared to 49% for the adjuvant therapy. That was quite an outstanding change. And again, noting the power of neoadjuvant treatment, really dictating the impact of anti PD-1, again, just with 3 doses moving from adjuvant into the neoadjuvant setting, and I think all of us were somewhat surprised to see that magnitude of a benefit. But it set up the current study very well, where we now look at combination therapy. Dr. Diwakar Davar: So let's move on to the phase 3 NADINA trial. Do you want to perhaps discuss the study design, particularly focusing on the EFS primary endpoint and maybe also touching on the different schedules? So, SWOG S1801 was a neoadjuvant study of 3 cycles of pembrolizumab and how did that compare and contrast to the neoadjuvant combination that was studied in NADINA? Dr. Jason Luke: Well, as you alluded to, NADINA investigated the regimen of nivolumab plus ipilimumab and compared that against adjuvant therapy with nivolumab alone. So, in the study, as you alluded, the dose and schedule of the two drugs used was nivolumab at 3 milligrams per kilogram, and ipilimumab with 1 milligram per kilogram. That was based on a series of signal finding and safety studies that had been previously done by the same group of authors identifying that as the optimal treatment regimen. And it's worth noting that's slightly different than the labeled indication that's generally used for those same drugs for metastatic melanoma, albeit that the NCCN also endorses this schedule. So, in the trial, 423 patients were randomized, 1:1 to receive either neoadjuvant therapy with those 2 doses of nivolumab plus ipilimumab as compared with standard adjuvant therapy with nivolumab following surgery.   Now, one interesting tweak was that there was an adaptive nature to the study, meaning that patients had a fiducial placed at the index lymph node, and after the neoadjuvant therapy in that arm, that lymph node was removed. And if the patient had a major pathological response, they did not go on to receive the adjuvant portion of the treatment. So it was adaptive because those patients who did very well to the neoadjuvant did not require the adjuvant portion. And in those patients who did not achieve a major pathological response, they could go on to have the adjuvant therapy. And that also included the BRAF therapy for those whose tumors were BRAF mutants.  It's also worth pointing out that the definition of event free survival was slightly different than in the S1801 study that was alluded to just a second ago. And here, EFS was defined from the date of randomization until progression due to melanoma or due to treatment. So that's slightly different than the definition in the S1801 trial. So, a somewhat complicated study, but I really applaud the authors because I think this study does mirror what we would likely be doing in actual clinical practice.  Dr. Diwakar Davar: So, just to briefly summarize the efficacy, and then to get your comments on this, the path response, the PCR rate was 47%. The major pathologic response rate, which is the proportion of patients with between 0% to 1/10% of residual viable tumors, was about 12%. And for a major pathologic response rate of 0% to 10% of 59%. And then the rest of the patients had either pathologic partial response, which was 10% to 50%, or pathologic non response or 50% or greater residual viable tumor, all assessed using central pathology grades. The one year RFS was 95% in the FDR patient population versus 76% in the pathologic partial response patient population, 57% in the pathologic non response patient population. So how do you view these results? Can you context the FDR rates and the EFS rates from NADINA relative to nivo-rela and also potentially SWOG 1801? Dr. Jason Luke: Well, I think these are very exciting results. I think that for those of us that have been following the field closely, they're actually not especially surprising because they mirror several studies that have come before them. When we put them in context with other studies, we see that these rates of major pathological response are consistent with what we've seen in phase 2 studies. They're relatively similar. Or I should say that the results from nivolumab and relatlimab, which was also pursued in a phase 2 study of somewhat similar design, are somewhat similar to this. So, combination immunotherapy does look to deliver a higher major pathological response than pembrolizumab alone, as was known in S1801. Which of course, the caveat being is these are cross control comparisons that we need to be careful about. So I think all of these are active regimens, and I think adding a second agent does appear to enhance the major pathologic response rates. When we look at the event free survival, we see something similar, which is that numerically it looks to be that combination immunotherapy delivers a higher event free survival rate. And that looks to be rather meaningful given the difference in the hazard ratios that were observed between these various studies. And here in the NADINA study, we see that 0.3 hazard ratio for EFS is just extremely impressive.  So the abstract then, from ourselves, out of these specific studies, what does this mean more broadly in the real world, where patients exist and the rest of the landscape for clinical trials? I think we can't take enough time to stop for a second and just think about what a revolution we've come forward in with immune checkpoint blockade and melanoma. When I started my career, now, more than 15 years ago, melanoma was the cancer that made cancer bad. And now here we say, in the highest risk of perioperative patients, we can deliver 2 doses of nivolumab and ipilimumab, and essentially half of the patients then don't need to go on, and more than half the patients don't need to go on to have a full surgery and don't need adjuvant therapy. And from what we could tell of a very, very low risk of every heavy recurrence of melanoma. Of course, there's the other half of patients where we still need to do better, but these are just fantastic results and I think highly meaningful for patients.   In the context of ongoing clinical trials, another abstract that was presented during the meeting was the update to the individualized neoantigen therapy, or V940 with pembrolizumab or against pembrolizumab alone. That's the KEYNOTE-942 study. In that study, they presented updated data at two and a half years for relapse free survival, noting a 75% rate without relapse. So those results are also highly intriguing. And these are in a similar population of very high risk patients. And so I think most of us believe that neoadjuvant therapy with this study in NADINA is now confirmed as the priority approach for patients who present with high-risk stage 3 disease. So that would be bulky disease picked up on a scan or palpable in a clinic. I think essentially all of us now believe patients should get preoperative immunotherapy. We can debate which approach to take, and it may vary by an individual patient's ability to tolerate toxicity, because, of course, multi agent immunotherapy does have increased toxicity relative to anti PD-1 alone. But we'll have to wait now for the full phase 3 results from the V940 individualized neoantigen therapy. And if those come forward, that will be an extremely attractive approach to think about for patients who did not achieve a major pathological response to neoadjuvant therapy, as well as of course to the other populations of patients with melanoma where we otherwise currently give adjuvant therapy stage 2B all the way through stage 4 resected. It's an amazing time to think about perioperative therapy in melanoma. Dr. Diwakar Davar: So this is clearly outstanding data, outstanding news. Congratulations to the investigators for really doing what is an investigative initiated trial conducted across multiple continents with a huge sample size. So this clearly appears to be, at this point in time at least, a de facto standard. But is this going to be FDA-approved, guideline-approved, or is it possible in your mind? Dr. Jason Luke: Well, that's an interesting question. This study was not designed with the intent to necessarily try to register this treatment regimen with the FDA. One would have to take a step back and say, with how powerful these data appear, it sort of seemed like it would be too bad if that doesn't happen. But all the same, I think the community and those of us who participate in guideline recommendations are fully supportive of this. So, I think we will see this move into compendium listings that support insurance approval, I think, very, very quickly. So, whether or not this actually becomes formally FDA approved or is in the guidelines, I think this should become the standard approach that is considered for patients, again presenting with high-risk stage 3 disease.  Dr. Diwakar Davar: Fantastic. So now we're going to go in and talk about a slightly different drug, but also from the melanoma context, and that is the safety and efficacy of RP1 with nivolumab in the context of patients with melanoma who are PD-1 failures. So, this is Abstract 9517. And in this abstract, our academic colleagues essentially talked about these data, and we'll start by describing what RP1 is. RP1 essentially is a HSV-1 based oncolytic immunotherapy. And RP1 expresses GM-CSF as well as a fusogenic protein, GALV-GP-R-. And in this abstract, Dr. Michael Wong from MD Anderson and colleagues are reporting the results of IGNYTE, which is a phase I trial of intratumoral RP1 co-administered with systemic nivolumab in patients with advanced metastatic treatment refractory cutaneous melanoma. And the data presented in this abstract represents data from a registration directed, abbreviated as RD, registration directed cohort of RP1 plus nivolumab in PD-1 refractory melanoma. So, let's start with the description of the cohort.  Dr. Jason Luke: Right. So, in this study, there were a total of 156 patients who were presented, and that included an initial safety and dose finding group of 16, as well as the RD cohort, as you noted, of 140 patients. And it's important to point out that this was a cohort that was selected for a very strict definition of progression on anti PD-1, or a combination immunotherapy as their immediately prior treatment. So, all of the patients in the cohort had exposure to anti PD-1, and 46% of them had anti PD-1 plus anti CTLA4, nivolumab and ipilimumab as their immediately prior therapy. This was also a group of relatively high-risk patients when one considers stage. So, within the stage 4 population, the entry here included 51% who had stage M1B, C, and D melanoma. And that is worth pointing out because this is an injectable therapy. So, trials like this in the past have tended to be biased towards earlier stage, unresectable or metastatic melanoma, meaning stage 3B, 3C, 3D and then stage 4m1a. Again, to emphasize the point here, these were pretreated patients who had a strict definition of anti PD-1 resistance, and over half of them, in fact, had high-risk visceral metastatic disease.  In that context, it's very interesting to observe that the overall response rate was described in the total population, as 31%, and that included 12% who achieved complete response. And so, again, to make sure it's clear, we're talking about a treatment where the oncolytic virus is injected into one or multiple sites of recurrent disease, and then the patients administer nivolumab as per standard. And so, I think these data are quite intriguing. Again, such a high- risk population and their maturity now, with a follow-up of over a year, I think, makes this look to be a very interesting treatment option.  Dr. Diwakar Davar: I guess on that topic of mature follow-up, it probably would be important for us to inform our audience that the top line data for the primary analysis was actually just released, I think, earlier today, and wherein the central confirmed objective response rate was 34% by modified RECIST and 33% by RECIST, clearly indicating that these responses, as you noted, very treatment refractory patient population, these responses were clearly very durable. So, you mentioned that there were responses seen in uninjected visceral lesions, responses seen in both PD-1 and PD-1 CTLA-4 refractory patients. Can you talk a little bit about the response rate in these high-risk subgroups, the uninjected visceral lesions, the patients who had both combination checkpoint and epidural refractory response rate by primary PD-1 resistance.  Dr. Jason Luke: Sure. You know, I think, again, to emphasize this point in the study, we saw that there were responses in the non-injected lesions, and I think it's really important to emphasize that. Some have referred to this as a putative abscopal like effect, similar to what is described in radiation. But it implies that local treatment with the oncolytic virus is triggering a systemic immune response. In the higher risk patient population, we'll note that whereas the overall response rate in PD-1 refractory patients was 34%, in the combination of PD-1 and CTLA-4 refractory patients, the response rate was 26%. So, [this is] still very good. And when we looked at that split by stage, as I alluded to before, in the population of patients that had, what you might call earlier unresectable diseases, so 3B through 4A, the response rate was 38%, and in the stage 4 M1b through M1d, it was 25%. So slightly lower, but still very good. And that would be as expected, because, of course, the patients with visceral metastatic disease have more advanced disease, but those response rates look quite good. Again, looking at the combination refractory population as well as the more high-risk disease. Dr. Diwakar Davar: So, clearly, these are very promising data and exciting times for multiple investigators in the field and the company, Replimune, as well. So, what are the next steps? I believe that a registration trial is planned, essentially, looking at this with the goal of trying to get this combination registered. Can you tell us a little bit about IGNYTE-3, the trial design, the control arm, and what you foresee this trial doing over the next couple of years?  Dr. Jason Luke: So, as this agent has been maturing, it's worth pointing out that the company that makes this molecule, called RP1, but I guess now we'll have to get used to this name vusolimogene oderparepvec as the actual scientific term, they have been having ongoing discussions with the FDA, and there is the potential that this agent could come forward on an accelerated path prior to the results being released from a phase 3 trial. That being said, the phase 3 confirmatory study, which is called the IGNYTE-3 study, is in the process of being launched now. And that's a study investigating this molecule in combination with nivolumab, as was alluded to earlier, and a randomized phase 3 design, where that combination is compared with a physician's choice, essentially a chemotherapy-based option.   In that study, it will be 400 patients with stage 3B through stage 4; patients will have progressed on anti PD-1, either as a combination or in sequence, and then come on the study to be randomized to either vusolimogene oderparepvec plus nivolumab versus that physician's choice. And the physician's choice includes chemotherapy agents, but also nivolumab plus relatlimab as another option, or an anti PD-1 monotherapy, if that's deemed to be a reasonable option by the treating investigator. And the primary endpoint of that study is overall survival. And unfortunately, in this highly refractory patient population, that's something that may not take long to identify with key secondary endpoints of progression free survival, as well as overall response rate. I'm quite enthusiastic about this study, given these data, which have now been centrally confirmed as you alluded to before. I think this is a very exciting area of investigation and really crossing my fingers that this may be perhaps the first locally administered therapy which does appear to have a systemic impact that can hold up in phase 3. Dr. Diwakar Davar: Very, very, very exciting results. And I guess it's worthwhile pointing out that this company also has got, I think, multiple studies planned with both RP1 and cutaneous squamous cell carcinoma in a solid organ transplant patient population where single agent activity has already been reported by Dr. Migden at prior meetings, as well as a novel trial of potentially RP2 metastatic uveal melanoma. So we'll now pivot to Abstract 6014. So, 6014 is a drug by a company known as Merus. Essentially, it's a very novel agent. Merus essentially is a company that is specialized in making bicyclics and tricyclics. And these are not bicycles or tricycles, but rather drugs that essentially are bispecific antibodies. And Merus essentially has come up with petosemtamab. I think we're going to have to figure out better names for all of these drugs at some point. But petosemtamab, or MCLA-158, essentially is a bicyclic, targeting both EGFR as well as LGR-5. So EGR-5, of course, is a known oncogenic driver in multiple tumor types, squamous, including non small cell lung cancer, cutaneous squamous cell carcinoma, but also head and neck squamous cell carcinoma. And LGR-5 essentially is leucine-rich repeat-containing G-protein coupled receptor 5, but it's a receptor in cancer stem cells and certainly highly expressed in head neck squam. And MCLA-158, or petosemtamab is a IgG one bispecific with ADCC-activity because of IgG1 backbone co-targeting EGFR and LGR5. Merus had earlier results that evaluated petosemtamab monotherapy. They defined the RP2D and second- and third-line head and neck blastoma patients with a respectable response rate of 37% investigator-assessed ORR with six months median DoR, and this was published by Ezra Cohen about a year or so ago.  In this abstract, Dr. Fayette and colleagues report on the results of the MCLA-158-CL01 trial, which is a trial of pembrolizumab plus petosemtamab in one front line head and neck squamous cell population. So maybe let's start with the description of the cohort. And it is a small trial, but we'll be able, I think, to dig into a little bit about why this might be exciting. Dr. Jason Luke: Yes. So, as alluded to, it's not the biggest trial as yet, but there were 26 patients with anti PD-1 treatment naive head and neck squamous cell carcinoma. And all the patients in the study did receive, as you alluded to, pembrolizumab plus petosemtamab. Based on the label for pembrolizumab, all the patients in this study were PDL-1 positive. So that's one point that it's worth pointing out to make sure that that's understood. This is the population of patients who would be expected to benefit from pembrolizumab in the first place. Now, in the abstract, they reported out only 10 response evaluable patients, but they updated that in the actual slides of presentation at the meeting. So among 24 patients that were alluded to, 67% were described as having had a response, although some of those were yet to be confirmed responses. And when it was evaluated by PDL-1 status, there didn't seem to be a clear enrichment of response in the PD-1 positive more than 20% group, as compared to the 1-19% group. That isn't especially surprising because that was a trend that one would see, presumably with pembrolizumab alone. But overall, I think these data are pretty exciting in terms of a preliminary study. Dr. Diwakar Davar: You know, you mentioned that the objective response rate was high, almost 60-something%. The prognosis of these patients is generally poor. The OS is typically thought of as between 6-15 months. And based on KEYNOTE-048, which was led by Dr. Burtness and colleagues, the standard of care in the setting is pembrolizumab +/- platinum based chemotherapy regimens. Allowing for the fact that we only have 10 patients here, how do you think these results stack up against KEYNOTE-048? And you made a very important point earlier, which was, by definition, pembro is on label only for the CPS. So PDL-1 score, at least in head and neck squamous cell carcinoma CPS and not TPS. But in the CPS 1% or greater patient population, where pembro is on label, how do these results stack up against the KEYNOTE-048 results. Dr. Jason Luke: Right. KEYNOTE-048 is considered the seminal study that dictates frontline treatment in head and neck cancer. And before we dive into this too far, we do want to acknowledge that here we're comparing 26 patients versus a phase 3 trial. So, we're not trying to get too far ahead of ourselves, but this is just a preliminary comparison. But in KEYNOTE-048, as you alluded to, two regimens were superior to chemotherapy. One was the pembrolizumab monotherapy, as well as pembrolizumab plus chemotherapy. So again, the study overall survival, of course, was much higher, the PDL-1 positive subgroup, which is what dictated the unlabeled use of this. But response to pembro monotherapy in that population of patients is still modest. We're talking about upwards of 20-30%. So, if you compare that to, again, preliminary evidence here from this trial of only 24 patients, that response rate of 60% seems extremely high. And so even if that were to come down somewhat in a larger data series of patients, that still looks to be quite promising as a treatment regimen, that might eventually even be chemotherapy sparing for this population of patients. I think this raises a lot of eyebrows that perhaps this dual targeting approach, EGFR and LDR-5, may bring something really important to the field that evolves it. Dr. Diwakar Davar: So, what are the next steps for petosemtamab? You mentioned that the activity was interesting. Are we going to see a larger trial? Any thoughts on where things are going to go?  Dr. Jason Luke: Well, based on the phase 2 data of petosemtamab alone, even without pembrolizumab, the molecule had already been given fast track designation by FDA, which means allowing for greater communication between the drug sponsor in the FDA and designing a seminal study design. One would assume that this trial will be rapidly expanded quite greatly, perhaps to 100 or 200 patients, to try to flush out what the real response rate is in a more meaningful number of patients. But I think these data will probably also trigger the design and probably near-term evaluation or expedited acceleration of a phase III clinical trial design that would potentially validate this against the current standard of care. So, I'm pretty excited. I think we'll see a lot more about this agent in the relatively near future. Dr. Diwakar Davar: So, finally, we'll pivot to the last abstract that we're going to talk about, which is Abstract 2504. It's a relatively interesting target, CCR8 monoclonal antibody. But this is the efficacy and safety of LM-108, and LM-108 is an anti CCR8 monoclonal antibody that is being developed by LaNova Medicine. And the results that are described, actually a pool set of results of combinations of LM-108 with anti PD-1, two separate anti PD-1, in patients with gastric cancer, mostly done ex-U.S., which is interesting because of this patient population, and it's a pool result of several, 3 phase 1 and 2 studies.  LM-108 is an Fc-optimized anti CCR8 monoclonal antibody that selectively depletes tumor infiltrating Tregs. The abstract reported a pooled analysis of three phase 1, 2 trials with 3 different NCT numbers that all evaluated the efficacy of LM-108 and anti PD-1 in patients with gastric cancer. So, let's start with the description of the cohort. Maybe, Jason, you can tell us a little bit about before you start, as you describe the cohort, sort of what we know, editorially speaking, about the difficulty with which Tregs depletion has been tried and obviously failed up until now in the tumor microenvironment. Dr. Jason Luke: Right. I think that's a really interesting comment. And so, for decades, in fact, targeting regulatory T-cell to alleviate immune exclusion in the tumor microenvironment has been of interest in immuno-oncology. And in preclinical mouse models, it seems quite clear that such an approach can deliver therapeutic efficacy. However, by contrast, in human clinical trials, various different Treg depleting strategies have been attempted, and there's really little to no evidence that depleting Tregs from human tumors actually can deliver therapeutic responses. And by that we're referring to CD-25 antibodies. The drug ipilimumab, the CTLA-4 antibody, was punitively described as a Tregs depleter preclinically, but that doesn't seem to be the case in patients. And so, in that background, this is quite an eye raiser that an anti CCR8 antibody could be driving this effect. Now, before we talk about the results of this trial, I will point out, however, that given the Fc-optimization, it's entirely possible that the Tregs are being depleted by this mechanism, but that more could also be going on. Because Fc gamma RII binding by this antibody that could be nonspecific also has the potential to trigger immune responses in the tumor microenvironment, probably mediated by myeloid cells. So I think more to come on this. If this turns out to be the first meaningful Tregs depletor that leads to therapeutic efficacy, that would be very interesting. But it's also possible this drug could have multiple mechanisms.  So, having said all of that, in the clinical trial, which was a pooled analysis, like you mentioned, of LM-108 in combination with anti PD-1 of a couple different flavors, there were 48 patients treated either with LM-108, with pembrolizumab, or with toripalimab, which is another anti PD-1 antibody. On the drug combination was, generally speaking, pretty well tolerated, noting grade 3 treatment related adverse events in the range of 38%, which is somewhat expected given combination immunotherapy. We talked about nivolumab and ipilimumab before, which, of course, gives even higher rates of immune-related adverse events, with the most common toxicities being anemia, lipase elevations, rash, ALC decrease; albeit, quite manageable. Dr. Diwakar Davar: So, what about the objective response rate? Can you contextualize the efficacy? And as you do that, maybe we'll think about what you'd expect in the context of, say, gastric cancer, especially in patients who've never really had a prior checkpoint inhibitor before. What do you think about the ORR? What do you think about the relative efficacy of this combination? Dr. Jason Luke: Well, so, in the study, they described overall response rate in the 36 patients as 36% and described immediate progression for survival of about 6.5 months. And so that was among patients who were treatment naive. And in second-line patients, they actually described an even higher response rate, although it was only 11 patients, but they're at 64%. And so, I think those data look to be somewhat interesting. When I was actually scrutinizing the actual data presented, it was of some interest to note that the quality of responses seemed to be about as good on the lower dose of LM-108, so 3 milligrams per kilogram as compared to 10 milligrams per kilogram. I think there's definitely more to learn here to try to optimize the dose and to fully understand what the overall efficacy of this treatment combination would be.  I would emphasize that in this disease, I think novel treatment strategies are certainly warranted. While anti PD-1 with chemotherapy has moved the needle in terms of standard of care treatment, it's really only a minor subset of patients who derive durable long-term benefit like we normally associate with immune checkpoint blockade. I think these are preliminary data. They're very intriguing.   You alluded to earlier that this population of patients was an Asian data set, and it is well known that the efficacy of chemotherapy and immunotherapy does appear to be somewhat enhanced in Asian populations, and that goes to distributions of metastasis and tumor microenvironment effects, etc. Very difficult to try to tease any of that out in this abstract, other than to look at these data and suggest that this is pretty interesting, both from a novel therapeutic approach, we talked about the Tregs consideration, but also straight up on the efficacy because I think if these data could hold up in a larger number of patients, and particularly in a western population of patients, I think it would be very intriguing. Dr. Diwakar Davar: Certainly, ASCO 2024 had a lot of interesting data, including data from targeted agents, the LAURA trial, ADCs. But just focusing on the immune therapy subset, we certainly saw a lot of great advances in patients who were treated with neoadjuvant as well as relapse refractory disease in the context of RP1 and then a couple of newer agents such as this petosemtamab as well as LM-108. And of course, we cannot forget to highlight the extended DMFS data from the pembro vaccine study from KEYNOTE-942.  Jason, as always, thank you for taking a little bit of time out of your extremely busy schedule to come and give us insights as to how these agents are impacting the landscape. We really value your input and so thank you very much.  Dr. Jason Luke: Thank you for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for your time today. You will find the links to all the abstracts that we discussed in the transcript of this episode. And finally, if you value the insights that you hear on this podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. So, thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers:   Dr. Diwakar Davar   @diwakardavar   Dr. Jason Luke   @jasonlukemd      Follow ASCO on social media:    @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn      Disclosures:       Dr. Diwakar Davar:     Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences    Consulting or Advisory Role: Instil Bio, Vedanta Biosciences    Consulting or Advisory Role (Immediate family member): Shionogi    Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences    Research Funding (Inst.): Zucero Therapeutics    Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy       Dr. Jason Luke:    Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine    Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure    Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)    Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

The USDA's NASS reports corn planting is done and a slight decline in crop condition over the last week. A bipartisan team of senators are calling for higher 2026 RFS volumes for 2026. 

It's Regency drama, gossip, and scandalous dances on this week's Doctor Who adventure, “Rogue!” The Bridgerton fans are losing their minds at this episode, including one Ruby Sunday, but what did the Three Who Rule think of this theatrical and romantic undertaking? Plus we pay tribute to William Russell, Doctor Who's original Man of Action and Knight of Jaffa, and we encourage you to listen to our own interview with Mr. Russell from 2012. Plus Big Finish celebrates 25 years, Tales of the TARDIS mystery, and this very podcast gets called out for both its numerous crimes and its place as one of the best Doctor Who podcasts! Will wonders never cease? Links: Support Radio Free Skaro on Patreon Review: Doctor Who S1E06 “Rogue” Returning to the Regency William Russell, Doctor Who legend, dies aged 99 Carole Ann Ford's tribute to William Russell RFS 298 with William Russell interview A new Tales of the TARDIS episode airing on BBC Four on June 20 Radio Times: Ncuti Gatwa and Millie Gibson star in Tales of the TARDIS Big Finish: Doctor Who: The Sirens of Time – Redux due November 2024 Big Finish: Dark Gallifrey: The War Master starts in July Big FInish: Doctor Who – The Lost Stories: Deathworld due in July Next Time: S1E07 “The Legend of Ruby Sunday” June 15, 630pm on BBC One Radio Times lists RFS and The Memory Cheats as one of the best DW podcasts

2:27:47 – Who could hang a name on you? RFS 300. Recorded 5/20/24 through 5/26/24. License for this track: Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License (creativecommons.org/licenses/by-nc-nd/3.0/). Attribution: by Shambles Constant, Falling Cow Productions – more info at onsug.comReleased May 2024 on The Overnightscape Underground (onsug.com), an Internet talk radio channel focusing on a freeform monologue […]